The global value of vaccination

Ehreth, Jenifer

doi:10.1016/s0264-410x(02)00623-0

Cited by 336 publications

(249 citation statements)

References 2 publications

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…1 Vaccination prevents an estimated 3 million deaths annually worldwide, including nearly 1.8 million from hepatitis B and measles combined. 2 Reductions in morbidity and mortality as a result of vaccination have had a significant economic impact as well: in most cases, the savings provided by vaccines far exceed their cost. For example, for every dollar spent on the measles-mumps-rubella, diphtheriatetanus-acellular pertussis, and Haemophilus influenzae type b vaccines, more than $21, $24, and $2 are saved in direct medical costs, respectively.…”

mentioning

confidence: 99%

“…For example, for every dollar spent on the measles-mumps-rubella, diphtheriatetanus-acellular pertussis, and Haemophilus influenzae type b vaccines, more than $21, $24, and $2 are saved in direct medical costs, respectively. 2 Notably, global savings in direct medical costs related to the eradication of smallpox in 1977 are estimated to exceed $300 million per year. 2 Managed care organizations should recognize that while vaccines provide optimal value, vaccines continue to be underused and undervalued.…”

mentioning

confidence: 99%

“…2 Notably, global savings in direct medical costs related to the eradication of smallpox in 1977 are estimated to exceed $300 million per year. 2 Managed care organizations should recognize that while vaccines provide optimal value, vaccines continue to be underused and undervalued. 2 This value is derived from the fact that most vaccines provide benefits that exceed both the direct medical and indirect societal costs of disease management, making these agents an obvious choice for implementation in the costdriven managed care setting.…”

mentioning

confidence: 99%

“…2 Managed care organizations should recognize that while vaccines provide optimal value, vaccines continue to be underused and undervalued. 2 This value is derived from the fact that most vaccines provide benefits that exceed both the direct medical and indirect societal costs of disease management, making these agents an obvious choice for implementation in the costdriven managed care setting. 2 The administration of traditional childhood vaccines has demonstrated substantial cost savings.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types

Armstrong¹

2010

JMCP

131

100

View full text Add to dashboard Cite

BACKGROUND: Vaccines have demonstrated cost-effectiveness in managed care through the prevention of disease. As new vaccines for previously untargeted conditions are developed, pharmacoeconomic modeling is becoming even more critical for the quantification of value in the health care industry. Two recently developed vaccines aimed at prevention of infection from human papillomavirus (HPV) types 16 and 18 have proven to be highly efficacious. HPV 16 and 18 are the 2 most common oncogenic strains of HPV and are responsible for 70% of cervical cancer cases worldwide. Persistent infection with an oncogenic HPV type is a known cause of cervical cancer. Therefore, prevention of cervical cancer via HPV vaccination may have a significant financial impact.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types

Armstrong¹

2010

JMCP

131

100

View full text Add to dashboard Cite

show abstract

“…Estas pueden ser reacciones sisté-micas, como fiebre, exantemas y linfadenopatías, o reacciones locales, como dolor, enrojecimiento y tumefacción en el sitio de la inyección. Tales reacciones generalmente no ocasionan daños permanentes (27).…”

Section: Reacciones Adversasunclassified

Eficacia y seguridad de una vacuna contra la leptospirosis humana en Cuba

Martínez¹,

Pérez²,

Quiñones

et al. 2004

Rev Panam Salud Publica

View full text Add to dashboard Cite

show abstract

Coverage and Equity of Childhood Vaccines in China

et al. 2022

View full text Add to dashboard Cite

ImportanceMeasuring vaccination coverage rates and equity is crucial for informing immunization policies in China.ObjectivesTo estimate coverage rates and multidimensional equity for childhood vaccination in China.Design, Setting, and ParticipantsThis cross-sectional study was conducted via a survey in 10 Chinese provinces between August 5 and October 16, 2019, among children ages 6 months to 5 years and their primary caregivers. Children’s vaccination records and their primary caregivers’ demographics and socioeconomic status were collected. Data were analyzed from November 2019 to March 2022.Main Outcomes and MeasuresVaccine coverage rates were measured as a percentage of National Immunization Program (NIP) and non-NIP vaccines administered before the day on which the child was surveyed. A multidimensional equity model applied a standardized approach to ranking individuals from least to most unfairly disadvantaged by estimating differences between observed vaccination status and estimated vaccination status as function of fair and unfair variation. Fair sources of variation in coverage included whether the child was of age to receive the vaccine, and unfair sources of variation included sex of the child and sociodemographic characteristics of caregivers. Absolute equity gaps (AEGs), concentration index values, and decompositions of factors associated with vaccine equity were estimated in the model.ResultsVaccine records and sociodemographic information of 5294 children (2976 [52.8%] boys and 2498 [47.2%] girls; age range, 6-59 months; 1547 children aged 12-23 months) and their primary caregivers were collected from 10 provinces. Fully immunized coverage under the NIP was 83.1% (95% CI, 82.0%-84.1%) at the national level and more than 80% in 7 provinces (province coverage ranged from 77.8% [95% CI, 74.3% to 81.3%] in Jiangxi to 88.4% [95% CI, 85.7%-91.1%] in Beijing). For most non-NIP vaccines, however, coverage rates were less than 50%, ranging from 1.8% (95% CI, 1.3%-2.2%) for the third dose of rotavirus vaccine to 67.1% (65.4% to 68.8%) for the first dose of the varicella vaccine. The first dose of Haemophilus influenzae type b vaccine had the largest AEG, at 0.603 (95% CI, 0.570-0.636), and rotavirus vaccine dose 3 had the largest concentration index value, at 0.769 (95% CI, 0.709-0.829). The largest share of non-NIP vaccine inequity was contributed by monthly family income per capita, followed by education level, place of residence, and province for caregivers. For example, the proportion of explained inequity for pneumococcal conjugate vaccine dose 3 was 40.94% (95% CI, 39.49%-42.39%), 22.67% (95% CI, 21.43%-23.9%), 27.15% (95% CI, 25.84%-28.46%), and 0.68% (95% CI, 0.44%-0.92%) for these factors, respectively.Conclusions and RelevanceThis cross-sectional study found that NIP vaccination coverage in China was high but there was inequity for non-NIP vaccines. These findings suggest that improvements in equitable coverage of non-NIP vaccination may be urgently needed to meet national immunization goals.

show abstract

The global value of vaccination

Cited by 336 publications

References 2 publications

Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types

Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types

Eficacia y seguridad de una vacuna contra la leptospirosis humana en Cuba

Coverage and Equity of Childhood Vaccines in China

Contact Info

Product

Resources

About